2010 - NANETS http://nanets.net/abstracts-archive/2010?format=html Thu, 15 Feb 2018 16:41:58 -0500 en-GB hourly 1 C26 – Risk of Metastatic Spread in Patients with Early-Stage, Surgically Resected Pancreatic Neuroendocrine Tumors http://nanets.net/abstracts-archive/2010/87-c26-risk-of-metastatic-spread-in-patients-with-early-stage-surgically-resected-pancreatic-neuroendocrine-tumors?format=html C26 – Risk of Metastatic Spread in Patients with Early-Stage, Surgically Resected Pancreatic Neuroendocrine Tumors Jonathan Strosberg MD, Asima Cheema MD, Jill Weber MPH, Domenico Coppola MD, Larry Kvols MD

 Download Poster

]]> http://nanets.net/abstracts-archive/2010/87-c26-risk-of-metastatic-spread-in-patients-with-early-stage-surgically-resected-pancreatic-neuroendocrine-tumors?format=html Jonathan Strosberg MD, Asima Cheema MD, Jill Weber MPH, Domenico Coppola MD, Larry Kvols MD

 Download Poster

]]> support@adgcommunications.com (Super User) 2010 Thu, 15 Feb 2018 16:41:58 -0500 O07 – Tumor and Normal Tissue Uptake of 68Ga-DOTA-tyr3- Octreotide after Treatment with Unlabeled Octreotide in Patients with Carcinoid Tumors and Pancreatic Neuroendocrine Tumors http://nanets.net/abstracts-archive/2010/104-o07-tumor-and-normal-tissue-uptake-of-68ga-dota-tyr3-octreotide-after-treatment-with-unlabeled-octreotide-in-patients-with-carcinoid-tumors-and-pancreatic-neuroendocrine-tumors?format=html O07 – Tumor and Normal Tissue Uptake of 68Ga-DOTA-tyr3- Octreotide after Treatment with Unlabeled Octreotide in Patients with Carcinoid Tumors and Pancreatic Neuroendocrine Tumors Yusuf Menda, MD, Michael Schultz, PhD, David Bushnell, MD, Thomas O’Dorisio, MD, M. Sue O’Dorisio, MD, PhD

]]> http://nanets.net/abstracts-archive/2010/104-o07-tumor-and-normal-tissue-uptake-of-68ga-dota-tyr3-octreotide-after-treatment-with-unlabeled-octreotide-in-patients-with-carcinoid-tumors-and-pancreatic-neuroendocrine-tumors?format=html Yusuf Menda, MD, Michael Schultz, PhD, David Bushnell, MD, Thomas O’Dorisio, MD, M. Sue O’Dorisio, MD, PhD

]]> support@adgcommunications.com (Super User) 2010 Thu, 15 Feb 2018 11:43:44 -0500 O06 – An Ongoing, Double-Blind, Randomized, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline® Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome http://nanets.net/abstracts-archive/2010/103-o06-an-ongoing-double-blind-randomized-placebo-controlled-clinical-trial-investigating-the-efficacy-and-safety-of-somatuline-depot-lanreotide-injection-in-the-treatment-of-carcinoid-syndrome?format=html O06 – An Ongoing, Double-Blind, Randomized, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline® Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome Edda Gomez-Panzani, Stephen Chang, Joëlle Blumberg and Veronique Fohanno

]]> http://nanets.net/abstracts-archive/2010/103-o06-an-ongoing-double-blind-randomized-placebo-controlled-clinical-trial-investigating-the-efficacy-and-safety-of-somatuline-depot-lanreotide-injection-in-the-treatment-of-carcinoid-syndrome?format=html Edda Gomez-Panzani, Stephen Chang, Joëlle Blumberg and Veronique Fohanno

]]> support@adgcommunications.com (Super User) 2010 Thu, 15 Feb 2018 11:43:43 -0500 O04 – Bayesian Adaptive Study Design for Efficient Dose Finding for an Octreotide Implant in Patients with Carcinoid Syndrome (CS) http://nanets.net/abstracts-archive/2010/101-o04-bayesian-adaptive-study-design-for-efficient-dose-finding-for-an-octreotide-implant-in-patients-with-carcinoid-syndrome-cs?format=html O04 – Bayesian Adaptive Study Design for Efficient Dose Finding for an Octreotide Implant in Patients with Carcinoid Syndrome (CS) Carla Chieffo, Stephen A. Bai, Yusong Chen, Theodore M. Danoff

]]> http://nanets.net/abstracts-archive/2010/101-o04-bayesian-adaptive-study-design-for-efficient-dose-finding-for-an-octreotide-implant-in-patients-with-carcinoid-syndrome-cs?format=html Carla Chieffo, Stephen A. Bai, Yusong Chen, Theodore M. Danoff

]]> support@adgcommunications.com (Super User) 2010 Thu, 15 Feb 2018 11:43:42 -0500 O05 – 177 Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms; First Trial in U.S.A http://nanets.net/abstracts-archive/2010/102-o05-177-lutetium-dota-octreotate-therapy-in-somatostatin-receptor-expressing-neuroendocrine-neoplasms-first-trial-in-u-s-a?format=html O05 – 177 Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms; First Trial in U.S.A Ebrahim S. Delpassand, M.D

]]> http://nanets.net/abstracts-archive/2010/102-o05-177-lutetium-dota-octreotate-therapy-in-somatostatin-receptor-expressing-neuroendocrine-neoplasms-first-trial-in-u-s-a?format=html Ebrahim S. Delpassand, M.D

]]> support@adgcommunications.com (Super User) 2010 Thu, 15 Feb 2018 11:43:42 -0500 O03 – Open-Label Phase 2 Clinical Trial of LX1606 / LX1032 in Europe: A Novel Agent for Reducing Serotonin Production in Carcinoid Syndrome http://nanets.net/abstracts-archive/2010/100-o03-open-label-phase-2-clinical-trial-of-lx1606-lx1032-in-europe-a-novel-agent-for-reducing-serotonin-production-in-carcinoid-syndrome?format=html O03 – Open-Label Phase 2 Clinical Trial of LX1606 / LX1032 in Europe: A Novel Agent for Reducing Serotonin Production in Carcinoid Syndrome Phil Brown, Kenny Frazier, Jessica Jackson, Shanna Jackson, Joel Frieman, Brian Zambrowicz

]]> http://nanets.net/abstracts-archive/2010/100-o03-open-label-phase-2-clinical-trial-of-lx1606-lx1032-in-europe-a-novel-agent-for-reducing-serotonin-production-in-carcinoid-syndrome?format=html Phil Brown, Kenny Frazier, Jessica Jackson, Shanna Jackson, Joel Frieman, Brian Zambrowicz

]]> support@adgcommunications.com (Super User) 2010 Thu, 15 Feb 2018 11:43:41 -0500 O02 – LX1606 / LX1032: A Serotonin Synthesis Inhibitor in a Randomized, Double-Blind Phase 2 Clinical Trial in the U.S. as a Novel Approach for Managing Gastrointestinal (GI) Symptoms in Carcinoid Syndrome http://nanets.net/abstracts-archive/2010/99-o02-lx1606-lx1032-a-serotonin-synthesis-inhibitor-in-a-randomized-double-blind-phase-2-clinical-trial-in-the-u-s-as-a-novel-approach-for-managing-gastrointestinal-gi-symptoms-in-carcinoid-syndrome?format=html O02 – LX1606 / LX1032: A Serotonin Synthesis Inhibitor in a Randomized, Double-Blind Phase 2 Clinical Trial in the U.S. as a Novel Approach for Managing Gastrointestinal (GI) Symptoms in Carcinoid Syndrome Phil Brown, Kenny Frazier, Jessica Jackson, Shanna Jackson, Joel Frieman, Brian Zambrowicz

]]> http://nanets.net/abstracts-archive/2010/99-o02-lx1606-lx1032-a-serotonin-synthesis-inhibitor-in-a-randomized-double-blind-phase-2-clinical-trial-in-the-u-s-as-a-novel-approach-for-managing-gastrointestinal-gi-symptoms-in-carcinoid-syndrome?format=html Phil Brown, Kenny Frazier, Jessica Jackson, Shanna Jackson, Joel Frieman, Brian Zambrowicz

]]> support@adgcommunications.com (Super User) 2010 Thu, 15 Feb 2018 11:43:40 -0500 O01 – Somatuline® Autogel® 120 mg (lanreotide) Evaluation of Tumor Progression-Free Survival in Patients with Non-Functioning Entero-Pancreatic Endocrine Tumors: An Ongoing, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study (the CLARINET Stu http://nanets.net/abstracts-archive/2010/98-o01-somatuline-autogel-120-mg-lanreotide-evaluation-of-tumor-progression-free-survival-in-patients-with-non-functioning-entero-pancreatic-endocrine-tumors-an-ongoing-double-blind-randomized-placebo-controlled-multicenter-study-the-clarinet-study?format=html O01 – Somatuline® Autogel® 120 mg (lanreotide) Evaluation of Tumor Progression-Free Survival in Patients with Non-Functioning Entero-Pancreatic Endocrine Tumors: An Ongoing, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study (the CLARINET Stu Joëlle Blumberg, Edda Gomez-Panzani, Séverine Latapie- Martinezand Nilani Liyanage

]]> http://nanets.net/abstracts-archive/2010/98-o01-somatuline-autogel-120-mg-lanreotide-evaluation-of-tumor-progression-free-survival-in-patients-with-non-functioning-entero-pancreatic-endocrine-tumors-an-ongoing-double-blind-randomized-placebo-controlled-multicenter-study-the-clarinet-study?format=html Joëlle Blumberg, Edda Gomez-Panzani, Séverine Latapie- Martinezand Nilani Liyanage

]]> support@adgcommunications.com (Super User) 2010 Thu, 15 Feb 2018 11:43:39 -0500 C36 – Randomized run-in study of Bevacizumab and Everolimus in low- to intermediate- grade neuroendocrine tumors (LGNETs) using perfusion CT (pCT) as functional biomarker http://nanets.net/abstracts-archive/2010/97-c36-randomized-run-in-study-of-bevacizumab-and-everolimus-in-low-to-intermediate-grade-neuroendocrine-tumors-lgnets-using-perfusion-ct-pct-as-functional-biomarker?format=html C36 – Randomized run-in study of Bevacizumab and Everolimus in low- to intermediate- grade neuroendocrine tumors (LGNETs) using perfusion CT (pCT) as functional biomarker James C. Yao, Alexandria Phan, Kenneth R. Hess, David Fogelman, Carmen Jacobs, Cecile G. Dagohoy, Colleen C. Leary, Chaan S. Ng

]]> http://nanets.net/abstracts-archive/2010/97-c36-randomized-run-in-study-of-bevacizumab-and-everolimus-in-low-to-intermediate-grade-neuroendocrine-tumors-lgnets-using-perfusion-ct-pct-as-functional-biomarker?format=html James C. Yao, Alexandria Phan, Kenneth R. Hess, David Fogelman, Carmen Jacobs, Cecile G. Dagohoy, Colleen C. Leary, Chaan S. Ng

]]> support@adgcommunications.com (Super User) 2010 Thu, 15 Feb 2018 11:42:08 -0500 C35 – RADIANT-2: A Phase III Trial of Everolimus + Octreotide LAR in Patients with Advanced Neuroendocrine Tumors (NET) http://nanets.net/abstracts-archive/2010/96-c35-radiant-2-a-phase-iii-trial-of-everolimus-octreotide-lar-in-patients-with-advanced-neuroendocrine-tumors-net?format=html C35 – RADIANT-2: A Phase III Trial of Everolimus + Octreotide LAR in Patients with Advanced Neuroendocrine Tumors (NET) James C. Yao, John D. Hainsworth, Eric Baudin, Marc Peeters, Dieter Hoersch, Lowell Anthony, Judith Klimovsky, Jessica St. Peter, Valentine Jehl, and Marianne Pavel

]]> http://nanets.net/abstracts-archive/2010/96-c35-radiant-2-a-phase-iii-trial-of-everolimus-octreotide-lar-in-patients-with-advanced-neuroendocrine-tumors-net?format=html James C. Yao, John D. Hainsworth, Eric Baudin, Marc Peeters, Dieter Hoersch, Lowell Anthony, Judith Klimovsky, Jessica St. Peter, Valentine Jehl, and Marianne Pavel

]]> support@adgcommunications.com (Super User) 2010 Thu, 15 Feb 2018 11:42:07 -0500 C34 – Clinical Effect of Temozolomide in Poorly Differentiated Endocrine Carcinoma (PDEC) after Progression on First-line Chemotherapy http://nanets.net/abstracts-archive/2010/95-c34-clinical-effect-of-temozolomide-in-poorly-differentiated-endocrine-carcinoma-pdec-after-progression-on-first-line-chemotherapy?format=html C34 – Clinical Effect of Temozolomide in Poorly Differentiated Endocrine Carcinoma (PDEC) after Progression on First-line Chemotherapy Staffan Welin MD, PhD, Halfdan SorbyeMD, PhD, Sigrunn Sebjornsen MD, Stian Knappskog, PhD, Christian Busch MD, Kjell Öberg MD,PhD

]]> http://nanets.net/abstracts-archive/2010/95-c34-clinical-effect-of-temozolomide-in-poorly-differentiated-endocrine-carcinoma-pdec-after-progression-on-first-line-chemotherapy?format=html Staffan Welin MD, PhD, Halfdan SorbyeMD, PhD, Sigrunn Sebjornsen MD, Stian Knappskog, PhD, Christian Busch MD, Kjell Öberg MD,PhD

]]> support@adgcommunications.com (Super User) 2010 Thu, 15 Feb 2018 11:42:06 -0500 C33 – Staged Second Look Laparaproscopy: A New Approach for Evaluating Ischemic Bowel Following Extensive Mesenteric Lymphadenectomy for Midgut Carcinoid http://nanets.net/abstracts-archive/2010/94-c33-staged-second-look-laparaproscopy-a-new-approach-for-evaluating-ischemic-bowel-following-extensive-mesenteric-lymphadenectomy-for-midgut-carcinoid?format=html C33 – Staged Second Look Laparaproscopy: A New Approach for Evaluating Ischemic Bowel Following Extensive Mesenteric Lymphadenectomy for Midgut Carcinoid Yi-Zarn Wang DDS, MD, Eugene Woltering MD and J. Philp Boudreaux MD

 Download Poster

]]> http://nanets.net/abstracts-archive/2010/94-c33-staged-second-look-laparaproscopy-a-new-approach-for-evaluating-ischemic-bowel-following-extensive-mesenteric-lymphadenectomy-for-midgut-carcinoid?format=html Yi-Zarn Wang DDS, MD, Eugene Woltering MD and J. Philp Boudreaux MD

 Download Poster

]]> support@adgcommunications.com (Super User) 2010 Thu, 15 Feb 2018 11:42:05 -0500 C32 – Radio-guided Exploration Facilitates Surgical Cytoreduction of Neuroendocrine Tumors http://nanets.net/abstracts-archive/2010/93-c32-radio-guided-exploration-facilitates-surgical-cytoreduction-of-neuroendocrine-tumors?format=html C32 – Radio-guided Exploration Facilitates Surgical Cytoreduction of Neuroendocrine Tumors Yi-Zarn Wang DDS, MD, , Abby E Gandolfi, BS., MS. , Lowell B. Anthony MD, Richard Campeau MD, Eugene Woltering MD. , , and J. Philip Boudreaux MD

 Download Poster

]]> http://nanets.net/abstracts-archive/2010/93-c32-radio-guided-exploration-facilitates-surgical-cytoreduction-of-neuroendocrine-tumors?format=html Yi-Zarn Wang DDS, MD, , Abby E Gandolfi, BS., MS. , Lowell B. Anthony MD, Richard Campeau MD, Eugene Woltering MD. , , and J. Philip Boudreaux MD

 Download Poster

]]> support@adgcommunications.com (Super User) 2010 Thu, 15 Feb 2018 11:42:04 -0500 C30 – Prospective analysis of clinical outcomes and prognostic factors in patients with neuroendocrine tumors (NETs) http://nanets.net/abstracts-archive/2010/91-c30-prospective-analysis-of-clinical-outcomes-and-prognostic-factors-in-patients-with-neuroendocrine-tumors-nets?format=html C30 – Prospective analysis of clinical outcomes and prognostic factors in patients with neuroendocrine tumors (NETs) Monica Ter-Minassian, Jennifer A. Chan, Christine S. Frauenhoffer, Susanne M. Hooshmand, Kofi Asomaning, Xihong Lin, David C. Christiani, Matthew H. Kulke

 Download Poster

]]> http://nanets.net/abstracts-archive/2010/91-c30-prospective-analysis-of-clinical-outcomes-and-prognostic-factors-in-patients-with-neuroendocrine-tumors-nets?format=html Monica Ter-Minassian, Jennifer A. Chan, Christine S. Frauenhoffer, Susanne M. Hooshmand, Kofi Asomaning, Xihong Lin, David C. Christiani, Matthew H. Kulke

 Download Poster

]]> support@adgcommunications.com (Super User) 2010 Thu, 15 Feb 2018 11:42:03 -0500 C31 – Sunitinib for treatment of pancreatic neuroendocrine tumors: Patient-reported outcomes and efficacy across patient subgroups in a Phase III trial http://nanets.net/abstracts-archive/2010/92-c31-sunitinib-for-treatment-of-pancreatic-neuroendocrine-tumors-patient-reported-outcomes-and-efficacy-across-patient-subgroups-in-a-phase-iii-trial?format=html C31 – Sunitinib for treatment of pancreatic neuroendocrine tumors: Patient-reported outcomes and efficacy across patient subgroups in a Phase III trial Aaron Vinik, Yung-Jue Bang, Jean-Luc Raoul, Juan Valle, Peter Metrakos, Dieter Hörsch, Beata Korytowsky, Rajiv Mundayat, Richard Chao, Eric Raymond

 Download Poster

]]> http://nanets.net/abstracts-archive/2010/92-c31-sunitinib-for-treatment-of-pancreatic-neuroendocrine-tumors-patient-reported-outcomes-and-efficacy-across-patient-subgroups-in-a-phase-iii-trial?format=html Aaron Vinik, Yung-Jue Bang, Jean-Luc Raoul, Juan Valle, Peter Metrakos, Dieter Hörsch, Beata Korytowsky, Rajiv Mundayat, Richard Chao, Eric Raymond

 Download Poster

]]> support@adgcommunications.com (Super User) 2010 Thu, 15 Feb 2018 11:42:03 -0500 C29 – Expectant Management of the Asymptomatic Primary is Safe in Patients Undergoing Chemoembolization for Metastatic Neuroendocrine Carcinoma http://nanets.net/abstracts-archive/2010/90-c29-expectant-management-of-the-asymptomatic-primary-is-safe-in-patients-undergoing-chemoembolization-for-metastatic-neuroendocrine-carcinoma?format=html C29 – Expectant Management of the Asymptomatic Primary is Safe in Patients Undergoing Chemoembolization for Metastatic Neuroendocrine Carcinoma Tassone, Patrick; Arrese, David; Klemanski, Dori; Shah, Manisha; Schmidt, Carl; and Bloomston, Mark

]]> http://nanets.net/abstracts-archive/2010/90-c29-expectant-management-of-the-asymptomatic-primary-is-safe-in-patients-undergoing-chemoembolization-for-metastatic-neuroendocrine-carcinoma?format=html Tassone, Patrick; Arrese, David; Klemanski, Dori; Shah, Manisha; Schmidt, Carl; and Bloomston, Mark

]]> support@adgcommunications.com (Super User) 2010 Thu, 15 Feb 2018 11:42:01 -0500 C28 – Survival Analyses of Pancreatic Neuroendocrine Tumors: Contrasting Institutional Databases with Population-based Studies http://nanets.net/abstracts-archive/2010/89-c28-survival-analyses-of-pancreatic-neuroendocrine-tumors-contrasting-institutional-databases-with-population-based-studies?format=html C28 – Survival Analyses of Pancreatic Neuroendocrine Tumors: Contrasting Institutional Databases with Population-based Studies Jonathan Strosberg MD, Thorvardur Halfdanarson MD H. Lee Moffitt Cancer Center, Tampa, Florida, USA ; University of Iowa, Iowa City, Iowa, USA

 Download Poster

]]> http://nanets.net/abstracts-archive/2010/89-c28-survival-analyses-of-pancreatic-neuroendocrine-tumors-contrasting-institutional-databases-with-population-based-studies?format=html Jonathan Strosberg MD, Thorvardur Halfdanarson MD H. Lee Moffitt Cancer Center, Tampa, Florida, USA ; University of Iowa, Iowa City, Iowa, USA

 Download Poster

]]> support@adgcommunications.com (Super User) 2010 Thu, 15 Feb 2018 11:42:00 -0500 C27 – Stage I Non-Functioning Neuroendocrine Tumors of the Pancreas: Surgery or Surveillance? http://nanets.net/abstracts-archive/2010/88-c27-stage-i-non-functioning-neuroendocrine-tumors-of-the-pancreas-surgery-or-surveillance?format=html C27 – Stage I Non-Functioning Neuroendocrine Tumors of the Pancreas: Surgery or Surveillance? Jonathan Strosberg MD, Asima Cheema MD, Larry Kvols MD

 Download Poster

]]> http://nanets.net/abstracts-archive/2010/88-c27-stage-i-non-functioning-neuroendocrine-tumors-of-the-pancreas-surgery-or-surveillance?format=html Jonathan Strosberg MD, Asima Cheema MD, Larry Kvols MD

 Download Poster

]]> support@adgcommunications.com (Super User) 2010 Thu, 15 Feb 2018 11:41:59 -0500 C25 – Prognostic Relevance of a Novel AJCC Staging Classification for Neuroendocrine Tumors of the Pancreas http://nanets.net/abstracts-archive/2010/86-c25-prognostic-relevance-of-a-novel-ajcc-staging-classification-for-neuroendocrine-tumors-of-the-pancreas?format=html C25 – Prognostic Relevance of a Novel AJCC Staging Classification for Neuroendocrine Tumors of the Pancreas Jonathan Strosberg MD, Asima Cheema MD, Jill Weber MPH, Domenico Coppola MD, Larry Kvols MD

 Download Poster

]]> http://nanets.net/abstracts-archive/2010/86-c25-prognostic-relevance-of-a-novel-ajcc-staging-classification-for-neuroendocrine-tumors-of-the-pancreas?format=html Jonathan Strosberg MD, Asima Cheema MD, Jill Weber MPH, Domenico Coppola MD, Larry Kvols MD

 Download Poster

]]> support@adgcommunications.com (Super User) 2010 Thu, 15 Feb 2018 11:41:58 -0500 C24 – Phase II study of sunitinib malate following hepatic artery embolization for metastatic neuroendocrine tumors http://nanets.net/abstracts-archive/2010/85-c24-phase-ii-study-of-sunitinib-malate-following-hepatic-artery-embolization-for-metastatic-neuroendocrine-tumors?format=html C24 – Phase II study of sunitinib malate following hepatic artery embolization for metastatic neuroendocrine tumors Jonathan Strosberg MD, Asima Cheema MD, Tiffany Campos, Tiffany Valone PA, Larry Kvols MD

 Download Poster

]]> http://nanets.net/abstracts-archive/2010/85-c24-phase-ii-study-of-sunitinib-malate-following-hepatic-artery-embolization-for-metastatic-neuroendocrine-tumors?format=html Jonathan Strosberg MD, Asima Cheema MD, Tiffany Campos, Tiffany Valone PA, Larry Kvols MD

 Download Poster

]]> support@adgcommunications.com (Super User) 2010 Thu, 15 Feb 2018 11:41:57 -0500